DAVITA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 133.5 USD | +0.56% |
|
+4.45% | +27.44% |
| Sales 2024 * | 12.57B 17.18B | Sales 2025 * | 13.11B 17.92B | Capitalization | 11.71B 16.01B |
|---|---|---|---|---|---|
| Net income 2024 * | 758M 1.04B | Net income 2025 * | 798M 1.09B | EV / Sales 2024 * | 1.72 x |
| Net Debt 2024 * | 9.93B 13.57B | Net Debt 2025 * | 10.1B 13.8B | EV / Sales 2025 * | 1.66 x |
| P/E ratio 2024 * |
15.5
x | P/E ratio 2025 * |
13.6
x | Employees | 70,000 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on DaVita Inc.
More recommendations
More press releases
| 1 day | +0.56% | ||
| 1 week | +4.45% | ||
| Current month | -3.29% | ||
| 1 month | -2.44% | ||
| 3 months | +24.58% | ||
| 6 months | +73.91% | ||
| Current year | +27.44% |
1 week
128.69
135.71
1 month
125.64138.25
Current year
103.40141.54
1 year
71.51141.54
3 years
65.28141.54
5 years
43.40141.54
10 years
43.40141.54
| Managers | Title | Age | Since |
|---|---|---|---|
Javier Rodriguez
CEO | Chief Executive Officer | 53 | 97-12-31 |
Joel Ackerman
DFI | Director of Finance/CFO | 59 | 17-02-26 |
Jeffrey Giullian
CTO | Chief Tech/Sci/R&D Officer | - | 19-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Nehra
BRD | Director/Board Member | 76 | 00-10-31 |
Barbara Desoer
BRD | Director/Board Member | 71 | 15-10-07 |
Phyllis Yale
BRD | Director/Board Member | 66 | 16-07-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.19% | 215 M€ | +10.68% | - | |
| 1.89% | 16 M€ | -3.37% | ||
| 0.93% | 2 M€ | +6.77% | ||
| 0.67% | 8 M€ | +5.48% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 133.5 | +0.56% | 477,673 |
| 24-04-25 | 132.8 | +0.02% | 519,286 |
| 24-04-24 | 132.7 | -0.87% | 472,887 |
| 24-04-23 | 133.9 | +1.05% | 402,045 |
| 24-04-22 | 132.5 | +3.68% | 673,396 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm
More quotes
DaVita Inc. specializes in providing dialysis services. Net sales break down by activity as follows:
- supply of dialysis services (95.3%): hemodialysis and peritoneal dialysis services for patients suffering from chronic renal failure. At the end of 2023, services are insured through 2,675 dialysis centers serving nearly 200,800 patients in the United States, and through 367 dialysis centers serving nearly 49,400 patients abroad;
- other (4.7%).
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
133.5
USD
Average target price
130.6
USD
Spread / Average Target
-2.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.44% | 11.71B | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +10.92% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -31.75% | 11.77B | |
| -1.42% | 11.72B | |
| -3.97% | 11.66B |
- Stock Market
- Equities
- DVA Stock
